Drug companies are required to submit the results of all drug trials to the FDA as part of new drug applications. After approval, these results are supposed to be made public, usually in the form of scientific publications. However, the new review published in PLoS Medicine found disturbing omissions and bias on the road to publication. The new analysis examined 164 trials for 33 new drugs that were approved by the FDA from January of 2001 to December 2002. By June 2007, one quarter of the trials were either published only in a partial form — as an abstract, or part of a pooled publication — or were not published at all [Science News]. Of 43 negative outcomes reported to the FDA, only 20 were later published. Nine percent of all published outcomes were more positive than those originally reported to the FDA.
The mechanisms behind the apparent publication bias is unclear, though it is understood that manufacturers of new drugs rely on publications to market their products, often with billions of dollars on the line. In discussions with investigators on unpublished trials, [the study authors] found no cases where companies prohibited the researchers from publishing. But they did describe two cases in which the investigators said they wanted to publish the results but had not had full cooperation from the sponsors [MedPage News].
“It confirms that this is not an open, transparent process. There is still the opportunity for sponsors of new products to try and tip the scales in their favor,” [Wired Science] said Arthur Levin, director of the Center for Medical Consumers. Since September, federal law requires all clinical trials to be registered in a publicly accessible database, ClinicalTrials.gov, run by the National Institutes of Health. But the law still does not require full disclosure of all outcomes.
No comments:
Post a Comment